Trial · NCT04885998
Results by group62
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 62
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part 1: Number of Participants Who Experienced Dose-limiting Toxicity (DLT) | Part 1 Cohort 1: Tarlatamab Dose A/Dose B + AMG 404 | 0 | Participants | ||
| Part 1: Number of Participants Who Experienced Dose-limiting Toxicity (DLT) | Part 1 Cohort 2: Tarlatamab Dose A/Dose C + AMG 404 | 1 | Participants | ||
| Part 1: Number of Participants Who Experienced Dose-limiting Toxicity (DLT) | Part 1 Cohort 3: Tarlatamab Dose A/Dose D + AMG 404 | 1 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Part 1 Cohort 1: Tarlatamab Dose A/Dose B + AMG 404 | Any TEAE | 7 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Part 1 Cohort 2: Tarlatamab Dose A/Dose C + AMG 404 | Any TEAE | 5 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Part 1 Cohort 3: Tarlatamab Dose A/Dose D + AMG 404 | Any TEAE | 3 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Part 2 Dose Expansion Cohort: Tarlatamab Dose A/Dose B + AMG 404 | Any TEAE | 8 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Part 1 Cohort 1: Tarlatamab Dose A/Dose B + AMG 404 | Any tarlatamab-related TEAE | 6 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Part 1 Cohort 2: Tarlatamab Dose A/Dose C + AMG 404 | Any tarlatamab-related TEAE | 5 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Part 1 Cohort 3: Tarlatamab Dose A/Dose D + AMG 404 | Any tarlatamab-related TEAE | 3 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Part 2 Dose Expansion Cohort: Tarlatamab Dose A/Dose B + AMG 404 | Any tarlatamab-related TEAE | 8 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Part 1 Cohort 1: Tarlatamab Dose A/Dose B + AMG 404 | Any AMG 404-related TEAE | 6 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Part 1 Cohort 2: Tarlatamab Dose A/Dose C + AMG 404 | Any AMG 404-related TEAE | 4 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Part 1 Cohort 3: Tarlatamab Dose A/Dose D + AMG 404 | Any AMG 404-related TEAE | 1 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Part 2 Dose Expansion Cohort: Tarlatamab Dose A/Dose B + AMG 404 | Any AMG 404-related TEAE | 6 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Part 1 Cohort 1: Tarlatamab Dose A/Dose B + AMG 404 | EP: Any TEAE | 2 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Part 1 Cohort 2: Tarlatamab Dose A/Dose C + AMG 404 | EP: Any TEAE | 0 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Part 1 Cohort 3: Tarlatamab Dose A/Dose D + AMG 404 | EP: Any TEAE | 1 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Part 2 Dose Expansion Cohort: Tarlatamab Dose A/Dose B + AMG 404 | EP: Any TEAE | 1 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Part 1 Cohort 1: Tarlatamab Dose A/Dose B + AMG 404 | EP: Any tarlatamab-related TEAE | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04885998/results